Myeloma Investment Fund

Self-sustaining venture fund

Venture Capital Active United States
Last updated 2026-06-18
Portfolio
2
in our dataset
Rounds participated
2
Rounds led
1
Rounds' value
$12.5M
total disclosed, rounds participated
Stages
—

About

Self-sustaining venture fund

Portfolio · 2

Nectin Therapeutics
Next-generation Immunotherapy Agents
Led ★ 1 round Latest: 2023-05
KAHR Medical
Fusion Proteins for Treating Cancer and Autoimmune Diseases
1 round $12.5M committed Latest: 2022-11

Investment activity

Portfolio by sector

Health Tech & Life Sciences2

Q&A

What is Myeloma Investment Fund's primary investment focus?
Myeloma Investment Fund focuses on the Health Tech & Life Sciences sector, with both of its portfolio companies operating in this area.
Can you name some of Myeloma Investment Fund's portfolio companies?
Myeloma Investment Fund's portfolio includes KAHR Medical, which develops fusion proteins for treating cancer and autoimmune diseases.
When did Myeloma Investment Fund make its most recent investment?
Myeloma Investment Fund made its most recent investment in May 2023.
What was Myeloma Investment Fund's first recorded investment?
Myeloma Investment Fund's first recorded investment occurred in November 2022.
What is the total amount raised by Nectin Therapeutics, a portfolio company of Myeloma Investment Fund?
Nectin Therapeutics, a portfolio company of Myeloma Investment Fund, has raised $36M.
What is the total amount raised by KAHR Medical, a portfolio company of Myeloma Investment Fund?
KAHR Medical, a portfolio company of Myeloma Investment Fund, has raised $118.27M.